{"pmid":32336528,"title":"Management of neurological care during the COVID-19 pandemic.","text":["Management of neurological care during the COVID-19 pandemic.","INTRODUCTION: The COVID-19 epidemic has led to the need for unprecedented decisions to be made to maintain the provision of neurological care. This article addresses operational decision-making during the epidemic. DEVELOPMENT: We report the measures taken, including the preparation of a functional reorganisation plan, strategies for hospitalisation and emergency management, the use of telephone consultations to maintain neurological care, provision of care at a unit outside the hospital for priority patients, decisions about complementary testing and periodic in-hospital treatments, and the use of a specific telephone service to prioritise patients with epileptic seizures. CONCLUSION: Despite the situation of confinement, neurology departments must continue to provide patient care through different means of operation. Like all elements of management, these must be evaluated.","Neurologia","Matias-Guiu, J","Porta-Etessam, J","Lopez-Valdes, E","Garcia-Morales, I","Guerrero-Sola, A","Matias-Guiu, J A","32336528"],"abstract":["INTRODUCTION: The COVID-19 epidemic has led to the need for unprecedented decisions to be made to maintain the provision of neurological care. This article addresses operational decision-making during the epidemic. DEVELOPMENT: We report the measures taken, including the preparation of a functional reorganisation plan, strategies for hospitalisation and emergency management, the use of telephone consultations to maintain neurological care, provision of care at a unit outside the hospital for priority patients, decisions about complementary testing and periodic in-hospital treatments, and the use of a specific telephone service to prioritise patients with epileptic seizures. CONCLUSION: Despite the situation of confinement, neurology departments must continue to provide patient care through different means of operation. Like all elements of management, these must be evaluated."],"journal":"Neurologia","authors":["Matias-Guiu, J","Porta-Etessam, J","Lopez-Valdes, E","Garcia-Morales, I","Guerrero-Sola, A","Matias-Guiu, J A"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32336528","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.nrl.2020.04.001","keywords":["asistencia neurologica","covid-19","covid-19","departamento de neurologia","gestion sanitaria","healthcare management","neurological care","neurology department","sars-cov-2","sars2-cov"],"topics":["Prevention"],"weight":1,"_version_":1665264685627211776,"score":8.574329,"similar":[{"pmid":32329044,"title":"Neurological complications of coronavirus and COVID-19.","text":["Neurological complications of coronavirus and COVID-19.","INTRODUCTION: Clinical and experimental studies have shown that the coronavirus family has a certain tropism for the central nervous system. Seven types of coronavirus can infect humans. DEVELOPMENT: Coronaviruses are not always confined to the respiratory tract, and under certain conditions they can invade the central nervous system and cause neurological pathologies. The potential for neuroinvasion is well documented in most human coronaviruses (OC-43, 229E, MERS and SARS) and in some animal coronaviruses (porcine haemagglutinating encephalomyelitis coronavirus). Neurological symptoms have been reported in patients affected by COVID-19, such as headache, dizziness, myalgia and anosmia, as well as cases of encephalopathy, encephalitis, necrotising haemorrhagic encephalopathy, stroke, epileptic seizures, rhabdomyolysis and Guillain-Barre syndrome, associated with SARS-CoV-2 infection. CONCLUSIONS: Future epidemiological studies and case records should elucidate the real incidence of these neurological complications, their pathogenic mechanisms and their therapeutic options.","Rev Neurol","Carod-Artal, F J","32329044"],"abstract":["INTRODUCTION: Clinical and experimental studies have shown that the coronavirus family has a certain tropism for the central nervous system. Seven types of coronavirus can infect humans. DEVELOPMENT: Coronaviruses are not always confined to the respiratory tract, and under certain conditions they can invade the central nervous system and cause neurological pathologies. The potential for neuroinvasion is well documented in most human coronaviruses (OC-43, 229E, MERS and SARS) and in some animal coronaviruses (porcine haemagglutinating encephalomyelitis coronavirus). Neurological symptoms have been reported in patients affected by COVID-19, such as headache, dizziness, myalgia and anosmia, as well as cases of encephalopathy, encephalitis, necrotising haemorrhagic encephalopathy, stroke, epileptic seizures, rhabdomyolysis and Guillain-Barre syndrome, associated with SARS-CoV-2 infection. CONCLUSIONS: Future epidemiological studies and case records should elucidate the real incidence of these neurological complications, their pathogenic mechanisms and their therapeutic options."],"journal":"Rev Neurol","authors":["Carod-Artal, F J"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329044","week":"202017|Apr 20 - Apr 26","doi":"10.33588/rn.7009.2020179","source":"PubMed","topics":["Diagnosis","Treatment","Mechanism"],"weight":1,"_version_":1664996914820546560,"score":297.32382},{"pmid":32284363,"title":"Acute neurology during the COVID-19 pandemic: Supporting the front line.","text":["Acute neurology during the COVID-19 pandemic: Supporting the front line.","Neurologists are affected by the COVID-19 pandemic in several key ways, including: a reduced ability to admit and accept in transfer critically ill neurologic patients due to census overflow; personal risk of exposure to COVID-19; and potentially redeployment of the acute neurologist workforce towards general medicine to assist our colleagues managing the surge of medical patients. As providers of inpatient and emergency-based acute neurologic care, we have been attempting to locally prepare for and manage the COVID-19 pandemic by focusing on 3 key areas: creating an integrated preparation plan that supports hospital measures; building an optimized, flexible, and redundant workforce; and maintaining a high level of neurologic care in our hospital and across our region despite limited transfer capabilities during the pandemic. This final concern is of key relevance in our region where our tertiary hospital supports numerous smaller community hospitals, typically by providing an open door to patient transfers. These hospitals are often in rural or frontier regions and are also affected by COVID-19, so not only are beginning to experience their own bed and clinician shortages,(1) but are understandably nervous about what the pandemic means for the availability of traditional support systems for other non-COVID-related diseases.","Neurology","Majersik, Jennifer J","Reddy, Vivek K","32284363"],"abstract":["Neurologists are affected by the COVID-19 pandemic in several key ways, including: a reduced ability to admit and accept in transfer critically ill neurologic patients due to census overflow; personal risk of exposure to COVID-19; and potentially redeployment of the acute neurologist workforce towards general medicine to assist our colleagues managing the surge of medical patients. As providers of inpatient and emergency-based acute neurologic care, we have been attempting to locally prepare for and manage the COVID-19 pandemic by focusing on 3 key areas: creating an integrated preparation plan that supports hospital measures; building an optimized, flexible, and redundant workforce; and maintaining a high level of neurologic care in our hospital and across our region despite limited transfer capabilities during the pandemic. This final concern is of key relevance in our region where our tertiary hospital supports numerous smaller community hospitals, typically by providing an open door to patient transfers. These hospitals are often in rural or frontier regions and are also affected by COVID-19, so not only are beginning to experience their own bed and clinician shortages,(1) but are understandably nervous about what the pandemic means for the availability of traditional support systems for other non-COVID-related diseases."],"journal":"Neurology","authors":["Majersik, Jennifer J","Reddy, Vivek K"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32284363","week":"202016|Apr 13 - Apr 19","doi":"10.1212/WNL.0000000000009564","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664636391696367616,"score":289.87064},{"pmid":32299636,"pmcid":"PMC7136883","title":"Should we expect neurological symptoms in the SARS-CoV-2 epidemic?","text":["Should we expect neurological symptoms in the SARS-CoV-2 epidemic?","INTRODUCTION: There is growing evidence that SARS-CoV-2 can gain access to the central nervous system (CNS). We revise the literature on coronavirus infection of the CNS associated with neurological diseases. DEVELOPMENT: Neurological symptoms were rarely reported in the SARS-CoV and MERS-CoV epidemics, although isolated cases were described. There are also reports of cases of neurological symptoms associated with CoV-OC43 and CoV-229E infection. The presence of neurological lesions, especially demyelinating lesions in the mouse hepatitis virus model, may explain the mechanisms by which coronaviruses enter the CNS, particularly those related with the immune response. This may explain the presence of coronavirus in patients with multiple sclerosis. We review the specific characteristics of SARS-CoV-2 and address the question of whether the high number of cases may be associated with greater CNS involvement. CONCLUSION: Although neurological symptoms are not frequent in coronavirus epidemics, the high number of patients with SARS-CoV-2 infection may explain the presence of the virus in the CNS and increase the likelihood of early- or delayed-onset neurological symptoms. Follow-up of patients affected by the SARS-CoV-2 epidemic should include careful assessment of the CNS.","Neurologia","Matias-Guiu, J","Gomez-Pinedo, U","Montero-Escribano, P","Gomez-Iglesias, P","Porta-Etessam, J","Matias-Guiu, J A","32299636"],"abstract":["INTRODUCTION: There is growing evidence that SARS-CoV-2 can gain access to the central nervous system (CNS). We revise the literature on coronavirus infection of the CNS associated with neurological diseases. DEVELOPMENT: Neurological symptoms were rarely reported in the SARS-CoV and MERS-CoV epidemics, although isolated cases were described. There are also reports of cases of neurological symptoms associated with CoV-OC43 and CoV-229E infection. The presence of neurological lesions, especially demyelinating lesions in the mouse hepatitis virus model, may explain the mechanisms by which coronaviruses enter the CNS, particularly those related with the immune response. This may explain the presence of coronavirus in patients with multiple sclerosis. We review the specific characteristics of SARS-CoV-2 and address the question of whether the high number of cases may be associated with greater CNS involvement. CONCLUSION: Although neurological symptoms are not frequent in coronavirus epidemics, the high number of patients with SARS-CoV-2 infection may explain the presence of the virus in the CNS and increase the likelihood of early- or delayed-onset neurological symptoms. Follow-up of patients affected by the SARS-CoV-2 epidemic should include careful assessment of the CNS."],"journal":"Neurologia","authors":["Matias-Guiu, J","Gomez-Pinedo, U","Montero-Escribano, P","Gomez-Iglesias, P","Porta-Etessam, J","Matias-Guiu, J A"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32299636","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.nrl.2020.03.001","keywords":["central nervous system","coronavirus","esclerosis multiple","mers-cov","mouse hepatitis virus","multiple sclerosis","neurological symptoms","sars-cov","sars-cov-2","sistema nervioso central","sintomas neurologicos","virus murino de la hepatitis"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664635401346744320,"score":245.29555},{"pmid":32329045,"title":"[E-health tools to overcome the gap in epilepsy care before, during and after COVID-19 pandemics].","text":["[E-health tools to overcome the gap in epilepsy care before, during and after COVID-19 pandemics].","INTRODUCTION: Epilepsy is a common chronic neurological disorder that affects around 50 million worldwide and there is an abundance of literature on the health care gap for this sector of the population. This gap will increase with the current pandemic due to COVID-19. AIM: To evaluate the current availability of digital health tools for the care of people with epilepsy according to the world medical literature and their use during said pandemic. DEVELOPMENT: We reviewed the publications in scientific journals in the last decade that had as their main topic the use of digital health tools or telemedicine focused on the care of patients with epilepsy, including 4 months after the national quarantines due to the appearance of the virus SARS-CoV-2. Seventeen publications were found on the use of telemedicine focused on epilepsy. The most widely used tools internationally are online platforms, followed by mobile applications, videoconferences, epileptic seizure capture systems, checklists, algorithms for understanding medical data, phone calls, tele-encephalography and text messages. None was published during the COVID-19 current pandemic. CONCLUSIONS: Although there is little literature on the use of digital health tools focused on epilepsy, there are several that can be used to fight the attention gap, especially in this global pandemic by COVID-19 that forces quarantines of people and communities for long periods. It is necessary to remove barriers and facilitate patient access to these new information technologies.","Rev Neurol","Santos-Peyret, A","Duron, R M","Sebastian-Diaz, M A","Crail-Melendez, D","Gomez-Ventura, S","Briceno-Gonzalez, E","Rito, Y","Martinez-Juarez, I E","32329045"],"abstract":["INTRODUCTION: Epilepsy is a common chronic neurological disorder that affects around 50 million worldwide and there is an abundance of literature on the health care gap for this sector of the population. This gap will increase with the current pandemic due to COVID-19. AIM: To evaluate the current availability of digital health tools for the care of people with epilepsy according to the world medical literature and their use during said pandemic. DEVELOPMENT: We reviewed the publications in scientific journals in the last decade that had as their main topic the use of digital health tools or telemedicine focused on the care of patients with epilepsy, including 4 months after the national quarantines due to the appearance of the virus SARS-CoV-2. Seventeen publications were found on the use of telemedicine focused on epilepsy. The most widely used tools internationally are online platforms, followed by mobile applications, videoconferences, epileptic seizure capture systems, checklists, algorithms for understanding medical data, phone calls, tele-encephalography and text messages. None was published during the COVID-19 current pandemic. CONCLUSIONS: Although there is little literature on the use of digital health tools focused on epilepsy, there are several that can be used to fight the attention gap, especially in this global pandemic by COVID-19 that forces quarantines of people and communities for long periods. It is necessary to remove barriers and facilitate patient access to these new information technologies."],"journal":"Rev Neurol","authors":["Santos-Peyret, A","Duron, R M","Sebastian-Diaz, M A","Crail-Melendez, D","Gomez-Ventura, S","Briceno-Gonzalez, E","Rito, Y","Martinez-Juarez, I E"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329045","week":"202017|Apr 20 - Apr 26","doi":"10.33588/rn.7009.2020173","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664996914949521409,"score":236.04886},{"pmid":32311114,"title":"Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic.","text":["Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic.","The COVID-19 pandemic has since March 2020 led to the need to re-think the delivery of services to patients with chronic dysimmune neuropathies. Telephone/video consultations have become widespread but have compounded concerns about objective evaluation. Therapeutic decisions need, more than ever before, to be considered in the best interests of both patients, and society, while not denying function-preserving/restoring treatment. Immunoglobulin therapy and plasma exchange, for those treated outside of the home, expose patients to the hazards of hospital or outpatient infusion centers. Steroid therapy initiation and continuation pose increased infectious risk. Immunosuppressant therapy similarly becomes highly problematic, with the risks of treatment continuation enhanced by uncertainties regarding duration of the pandemic. The required processes necessitate considerable time and effort especially as resources and staff are re-deployed to face the pandemic, but are essential for protecting this group of patients and as an integral part of wider public health actions. This article is protected by copyright. All rights reserved.","Muscle Nerve","Rajabally, Yusuf A","Goedee, H Stephan","Attarian, Shahram","Hartung, Hans-Peter","32311114"],"abstract":["The COVID-19 pandemic has since March 2020 led to the need to re-think the delivery of services to patients with chronic dysimmune neuropathies. Telephone/video consultations have become widespread but have compounded concerns about objective evaluation. Therapeutic decisions need, more than ever before, to be considered in the best interests of both patients, and society, while not denying function-preserving/restoring treatment. Immunoglobulin therapy and plasma exchange, for those treated outside of the home, expose patients to the hazards of hospital or outpatient infusion centers. Steroid therapy initiation and continuation pose increased infectious risk. Immunosuppressant therapy similarly becomes highly problematic, with the risks of treatment continuation enhanced by uncertainties regarding duration of the pandemic. The required processes necessitate considerable time and effort especially as resources and staff are re-deployed to face the pandemic, but are essential for protecting this group of patients and as an integral part of wider public health actions. This article is protected by copyright. All rights reserved."],"journal":"Muscle Nerve","authors":["Rajabally, Yusuf A","Goedee, H Stephan","Attarian, Shahram","Hartung, Hans-Peter"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311114","week":"202017|Apr 20 - Apr 26","doi":"10.1002/mus.26896","keywords":["covid-19","chronic inflammatory demyelinating polyneuropathy","dysimmune","multifocal motor neuropathy","pandemic","paraproteinemic neuropathy"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Immunoglobulin","Steroid"],"_version_":1664632501530787842,"score":231.25023}]}